Please wait while the formulary information is being retrieved.
INTELENCE (ETRAVIRINE)
- HIV infection
100 mg tablet
- 2 tablets (200 mg) by oral route 2 times per day after meals
200 mg tablet
- 1 tablet (200 mg) by oral route 2 times per day after meals
25 mg tablet
- Dosage information is not available
100 mg tablet
- 2 tablets (200 mg) by oral route 2 times per day after meals
200 mg tablet
- 1 tablet (200 mg) by oral route 2 times per day after meals
25 mg tablet
- Dosage information is not available
HIV infection
- 2 tablets (200 mg) by oral route 2 times per day after meals
- 1 tablet (200 mg) by oral route 2 times per day after meals
- Aptivus
- atazanavir
- Atripla
- B cplx-C-St.Johnwrt-K.&S.ginsg
- Belladonna-phenobarbital
- calcium-mag-B complex-D3-hrb61
- carbamazepine
- Carbatrol
- Cerebyx
- Cold & Flu Fighter
- Complera
- delavirdine
- Dilantin
- Dilantin Extended
- Dilantin Infatabs
- Dilantin Kapseal
- Dilantin-125
- Donnatal
- Edurant
- efavirenz
- efavirenz-emtricitabin-tenofov
- elvitegr-cobicist-emtric-tenof
- emtricitab-rilpivirine-tenofov
- Epitol
- Equetro
- Fatigue Relief Complex
- fosamprenavir
- fosphenytoin
- isoniazid-rifamp-pyrazinamide
- Lexiva
- Luminal
- nevirapine
- phenobarb-hyoscy-atropine-scop
- phenobarbital
- phenobarbital sodium
- Phenytek
- phenytoin
- phenytoin sodium
- phenytoin sodium extended
- Priftin
- Rescriptor
- Reyataz
- Rifadin
- Rifamate
- rifampin
- rifampin-isoniazid
- rifapentine
- Rifater
- rilpivirine
- St. John's wort
- Stribild
- Sustiva
- Tegretol
- Tegretol Xr
- tipranavir
- Viramune
- Viramune Xr
- vit C-St. John wort-elder-hb30
- Women's Complex
Contraindicated
- axitinib
- bedaquiline
- Bosulif
- bosutinib
- citalopram
- clopidogrel
- Crixivan
- dolutegravir
- enzalutamide
- guanfacine
- indinavir
- Inlyta
- Intuniv Er
- Kaletra
- lopinavir-ritonavir
- Mycobutin
- Norvir
- Norvir Soft Gelatin
- Olysio
- Plavix
- rifabutin
- ritonavir
- simeprevir
- Sirturo
- Tenex
- Tivicay
- Xtandi
Severe
Moderate
- amoxicil-clarithromy-lansopraz
- Biaxin
- Biaxin Xl
- Biaxin Xl Pak
- Celexa
- clarithromycin
- Omeclamox-pak
- omeprazole-clarith-amoxicillin
- Prevpac
- Lactating mother
Contraindicated
- None
Severe
Moderate
- None
INTELENCE (ETRAVIRINE)
- HIV infection
- None
- Diarrhea
- Peripheral neuropathy
- Skin rash
More Frequent
Severe
Less Severe
- Increased alanine transaminase
- Increased aspartate transaminase
- Hypertriglyceridemia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Angina
- Angioedema
- Atrial fibrillation
- Bloody vomit
- Bronchospastic pulmonary disease
- Diabetes mellitus
- DRESS syndrome
- Drug-induced hepatitis
- Dyspnea
- Erythema multiforme
- Graves' disease
- Guillain-barre syndrome
- Hemolytic anemia
- Hemorrhagic stroke
- Hepatic failure
- Hepatomegaly
- Hypersensitivity drug reaction
- Pancreatitis
- Polymyositis
- Renal failure
- Rhabdomyolysis
- Seizure disorder
- Steatosis of liver
- Stevens-johnson syndrome
- Toxic epidermal necrolysis
Less Severe
- Abdominal distension
- Acute confusion
- Anorexia
- Blurred vision
- Constipation
- Disturbance of attention
- Dream disorder
- Drowsy
- Dry skin
- Eosinophilia
- Flatulence
- Gastritis
- Gastroesophageal reflux disease
- Gynecomastia
- Hyperhidrosis
- Hypersomnia
- Hypesthesia
- Lipodystrophy associated with HIV
- Memory impairment
- Mixed hyperlipidemia
- Myopathy
- Nervousness
- Night sweats
- Nightmares
- Sleep disorder
- Stomatitis
- Symptoms of anxiety
- Syncope
- Tremor
- Vertigo
- Vomiting
- Xerostomia
Contraindicated
None
Severe Precaution
Etravirine
Not recommended age < 2 years. Risk of virologic failure and resistance due to lower AUC.
- 1 Day – 2 Years
- Not recommended age < 2 years. Risk of virologic failure and resistance due to lower AUC.
Management or Monitoring Precaution
Etravirine
Increased incidence of rash in pediatrics.
- 2 Years – 18 Years
- Increased incidence of rash in pediatrics.
Etravirine
- Severity Level:
2
- Additional Notes: Insufficient human data available.
Contraindicated
Etravirine
Cdc does not recommend breastfeeding in hiv-positive women
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Excreted | Not known; no or inclusive data | Cdc does not recommend breastfeeding in hiv-positive women |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| HIV infection | |
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
| 0-9 | A-Z |
|---|---|
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
Formulary Reference Tool